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The CRISPR patent decision didn’t get the science right. That
doesn’t mean it was wrong
By Jacob S. Sherkow
September 11, 2018

Adobe

The CRISPR patent dispute1 between the University of California, Berkeley, and the Broad Institute is
finally over2. As almost everyone following the case predicted, the U.S. Court of Appeals for the Federal
Circuit affirmed Monday the U.S. patent office’s decision3 that there was “no interference-in-fact”
between UC Berkeley’s patent application and more than a dozen Broad patents. In plain English: Broad
researcher Feng Zhang’s CRISPR patents were sufficiently inventive over the UC Berkeley’s patent
applications with Jennifer Doudna and Emmanuelle Charpentier.
Many scientists disagree with the decision, believing that it fails to comport with how molecular biology
is actually practiced. I agree with them. But that doesn’t make the Federal Circuit’s decision wrong. In
fact, I think its decision is absolutely correct.
The reason has to do with standards of review — the standards courts use to weigh evidence, limit their
authority, and make decisions. Like criminal law’s “beyond a reasonable doubt” standard, standards of
review are incredibly important for many legal cases. They’re how much one side needs to prove
something and, failing that, who should win.
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The standard of review in the CRISPR patent dispute was the “substantial evidence” standard: whether a
reasonable trier of fact (one or more people who determine the facts in a legal proceeding) based its
opinion on substantial evidence. To be clear, that doesn’t mean the trier of fact got things correct, or even
whether there was more evidence for the other side. Rather, the substantial evidence standard means only
that a fact-finder based its decision on substantial enough evidence to be reasonable.
Related: 1
Appeals court upholds CRISPR patents awarded to the Broad Institute 1

And there was substantial enough evidence for the Patent Office to determine that Zhang’s application of
Doudna and Charpentier’s CRISPR-Cas9 system, which they developed in bacteria, to more complex
eukaryotic cells (cells like human cells that have nuclei) constituted a significant enough advance to be its
own invention. The patent office considered the scientific difficulties in getting other nucleic acid geneediting systems to work in eukaryotes; statements submitted by experts from both sides, such as UC
Berkeley’s own expert4 saying that there was “no guarantee that Cas9 would work effectively on a
chromatin target or that the required DNA-RNA hybrid can be stabilized in that context,” and ultimately
statements by Doudna herself that called the gap between bacteria and human cells a “huge bottleneck.”1
I, and many scientists5 as well, think that holding these offhanded statements against Doudna is both
unfortunate and bad as a matter of policy. But they were evidence, and the patent office was correct to
consider them as such. Considered as a whole, those statements, the testimony of experts, and scientific
difficulties in getting previous gene-editing systems to work in eukaryotic cells represent at least
substantial evidence.
This doesn’t mean I agree with the patent office’s interpretation of the science. In its original decision,
the patent office wrote that moving previous gene-editing systems from bacteria to eukaryotic cells
suffered from numerous problems: “differences in gene expression, protein folding, cellular
compartmentalization, chromatin structure, cellular nucleases, intracellular temperature, intracellular ion
concentrations, intracellular pH, and the types of molecules in prokaryotic versus eukaryotic cells.”
These problems were real and shouldn’t be discounted. But, as I wrote in article for EMBO Reports6 last
year, they were widely known to scientists at the time who could have solved each with a road map of
solutions. “[D]ifferential gene expression can be controlled by selecting appropriate promoters; protein
folding can, in some instances, be made uniform by certain optimization techniques; chromatin structure
can be altered by histone modification; nucleases can be blocked; temperature can be regulated; pH can
be buffered; and so on,” I wrote. As a matter of patent law, however, this experimental road map isn’t
enough — it does not provide, in patent parlance, a “reasonable expectation of success.”
This illustrates, I think, a classic disconnect between the legal standards of patent law and the realities of
scientific research. There are others, which I have also written about at length: on how science and patent
law treat reproducibility9; how they treat genetic datasets10; on what, exactly, is a “law of nature.”11
You could say that as a former laboratory scientist turned patent law professor, this is a particular
academic interest of mine. But my view of what’s best is not the same as what the law actually is. The
CRISPR patent decision may not have gotten the science right. But that doesn’t make it wrong as a legal
matter.
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If you don’t agree with the Federal Circuit’s decision, you may be in good company. The law can
sometimes be wrong as a matter of both policy and practicality. But, at least ideally, the law provides a
previously agreed-upon, neutral set of rules to decide disputes. When the law no longer works, it’s
ultimately the job of Congress to change the law. And although this ideal is routinely flaunted in practice,
it’s still a model to live by.
In fact, it’s something scientists themselves should be familiar with. When the facts stop fitting the
model, you change the model, not the facts. You dust yourself off, come up with new hypotheses and
new experiments to explain the world, and try again.
Jacob S. Sherkow, J.D., is professor of law at the Innovation Center for Law and Technology12 at New
York Law School.
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